L-Arginine and Alzheimer's disase

International Journal of Clinical and Experimental Pathology

Volumn 2, Issue 3, 2009, Pages 211-238

  Yi, Jing ^a   Horky, Laura L ^b   Friedlich, Avi L ^a   Shi, Ying ^c   Rogers, Jack T ^a   Huang, Xudeng ^a,c  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c Department of Radiology   (United States)

Author keywords

Alzheimer's disease; Arginase; L arginine; Neurogenesis; Nitric oxide; Nitric oxide synthase; Polyamines; Stem cells

Indexed keywords

EID: 67149092204     PISSN: None     EISSN: 19362625     Source Type: Journal    
DOI: None     Document Type: Review

References (385)

1. Evans DA, Funkenstein HH, Altert MS, Scherr PA, Cook NR, Chown MJ, Herbert LE, Hennekens CH and Taylor JO. Prevalence of Alzheimer's disease in a community population of older persons. JAMA 1989;262: 2551-2556.
2. U.S. Government Printing Office, Washington, DC. National Institute on Aging (1995) Progress Report on Alzheimer's Disease. NIH Publication 95-3994.
3. Selkoe DJ. Alzheimer's disease: genes, proteins, and therapy. Physiol Rev 2001;81: 741-766.
4. Yaari R and Corey-Bloom J. Alzheimer's disease. Semin Neurol 2007;27:32-41.
5. Goedert M and Spillantini MG. A century of Alzheimer's disease. Science 2006;314:777-781.
6. Mattson MP. Pathways towards and away from Alzheimer's disease. Nature 2004;430: 631-639.
7. Rose WC. The nutritional significance of the amino acids. Physiol Rev 1938;18:109-136.
8. Hedin SG. Eine methode das lysin zu isolieren, nebst einigen Bemerkungen uber das lysatinin. Z Physiol Chem 1895;21:297-305.
9. Schulze E and Steiger E. Uber das Arginin. Z Physiol Chem 1886;11:43-65.
10. Moncada S and Higgs A. The L-arginine-nitric oxide pathway. N Engl J Med 1993;329: 2002-2012.
11. Sidney M and Morris Jr. Regulation of enzymes of the urea cycle and arginine metabolism. Annu Rev Nutr 2002;22: 87-105.
12. Forstermann U, Closs EI, Pollock JS, Nakane M, Schwarz P, Gath I and Kleinert H. Nitric oxide synthase isozymes. Characterization, purification, molecular cloning, and functions. Hypertension 1994;23:1121-1131.
13. Boger RH. The pharmacodynamics of L-arginine. J Nutr 2007;137(Suppl 2):1650S-1655S.
14. Malinski T. Nitric oxide and nitroxidative stress in Alzheimer's disease. J Alzheimers Dis 2007;11:207-218.
15. Loscalzo J. What we know and don't know about L-arginine and NO. Circulation 2000; 101:2126-2129.
16. Siasos G, Tousoulis D, Antoniades C, Stefanadi E and Stefanadis C. L-Arginine, the substrate for NO synthesis: An alternative treatment for premature atherosclerosis? Int J Cardiol 2007;116:300-308.
17. Forstermann U, Boissel JP and Kleinert H. Expressional control of the constitutive isoforms of nitric oxide synthase (NOS I and NOS III). FASEB J 1998;12:773-790.
18. Boger RH, Bode-Boger SM and Frolich JC. The L-arginine - nitric oxide pathway: Role in atherosclerosis and therapeutic implications. Atherosclerosis 1996;127:1-11.
19. Cooke JP and Dzau VJ. Nitric oxide synthase: role in the genesis of vascular disease. Annu Rev Med 1997;48:489-509.
20. Cooke JP. The pivotal role of nitric oxide for vascular health. Can J Cardiol 2004;20(Suppl B):7B-15B.
21. Li XA, Everson W and Smart EJ. Nitric oxide, caveolae, and vascular pathology. Cardiovasc Toxicol 2006;6:1-13.
22. Napoli C, de Nigris F, Williams-Ignarro S, Pignalosa O, Sica V and Ignarro LJ. Nitric oxide and atherosclerosis: An update. Nitric Oxide 2006;15:265-279.
23. Bohme GA, Bon C, Lemaire M, Reibaud M, Piot O, Stutzmann JM, Doble A and Blanchard JC. Altered synaptic plasticity and memory formation in nitric oxide synthase inhibitor-treated rats. Proc Natl Acad Sci USA 1993;90: 9191-9194.
24. Paakkari I and Lindsberg P. Nitric oxide in the central nervous system. Ann Med 1995;27: 369-377.
25. Potenza MA, Nacci C and Mitolo-Chieppa D. Immunoregulatory effects of L-arginine and therapeutical implications. Curr Drug Targets Immune Endocr Metabol Disord 2001;1:67-77.
26. Jobgena WS, Friedb SK, Fuc WJ, Meiningerd CJ and Wu G. Regulatory role for the arginine-nitric oxide pathway in metabolism of energy substrates. J Nutr Biochem 2006; 17:571-588.
27. Wu G and Morris SM Jr. Arginine metabolism: nitric oxide and beyond. Biochem J 1998;336: 1-17.
28. Iyer R, Jenkinson CP, Vockley JG, Kern RM, Grody WW and Cederbaum S. The human arginases and arginase deficiency. J Inherit Metab Dis 1998;1:86-100.
29. Sidney M and Morris SM Jr. Regulation of enzymes of the urea cycle and arginine metabolism. Annu Rev Nutr 2002;22:87-105.
30. Glass RD and Knox WE. Arginase isozymes of rat mammary gland, liver and other tissues. J Biol Chem 1973;248:5785-5789.
31. Kaysen GA and Strecker HJ. Purification and properties of arginase of rat kidney. Biochem J 1973;133:779-788.
32. Spector EB, Rice SCH and Cederbaum SD. Immunologic studies of arginase in tissues of normal human adults and arginase-deficient patients. Pediatr Res 1983;17:941-944.
33. Grody WW, Argyle C, Kern RM, Dizikes GJ, Spector EB, Strickland AD, Klein D and Cederbaum SD. Differential expression of the two human arginase genes in hyperargininemia: enzymatic pathologic and molecular analysis. J Clin Invest 1989;83: 602-609.
34. Lange PS, Langley B, Lu P and Ratan RR. Novel roles for arginase in cell survival, regeneration, and translation in the central nervous system. J Nutr 2004;134(Suppl): 2812S-2817S.
35. Becker-Catania SG, Gregory TL, Yang Y, Gau CL, de Vellis J, Cederbaum SD and Iyer RK. Loss of arginase I results in increased proliferation of neural stem cells. J Neurosci Res 2006;84:735-746.
36. Boeshore KI, Schreiber RC, Vaccariello SA, Sachs HH, Salazer R, Lee J, Ratan RR, Leahy P and Zigmond RE. Novel changes in gene expression following axotomy of a sympathetic ganglion: a microarray analysis. J Neurobiol 2004;59:216-235.
37. Yu H, Iyer RK, Kern RT, Rodriquez WI, Grody WW and Cederbaum SD. Expression of arginase isozymes in mouse brain. J Neurosci Res 2001;66:406-422.
38. Yu H, Iyer, RK, Yoo PK, Kern RM, Grody WW and Cederbaum SD. Arginase expression in mouse embryonic development. Mech 2002; 115:151-155.
39. Terheggen HF, Schwenk A, Lowenthal A, van Sande M and Colombo JPZ. Hyperargininemia with arginase deficiency, a new familial metabolic disease: clinical aspects. Kinderheilk 1970;107:298-312.
40. Scaglia F and Lee B. Clinical, biochemical, and molecular spectrum of hyperargininemia due to arginase I deficiency. Am J Med Genet C Semin Med Cenet 2006;142:113-120.
41. Cederbaum SD, Shaw KNF, Spector EB, Verity MA, Snodgrass PJ and Sugarman GI. Hyperargininemia due to arginase deficiency. Pediatr Res 1979;13:827-833.
42. Spector EB, Rice SCH and Cederbaum SD. Immunologic studies of arginase in tissues of normal human adults and arginase-deficient patients. Pediatr Res 1983;17:941-944.
43. Grody WW, Kern RM, Klein D, Dodson AE, Wissman PB, Barsky SH and Cederbaum SD. Arginase deficiency manifesting delayed clinical sequelae and induction of a kidney arginase isozyme. Hum Genet 1993;91:1-5.
44. Spector EB, Jenkinson CP, Grigor MR, Kern RM and Cederbaum SD. Subcellular location and differential antibody specificity of arginase in tissue culture and whole animals. Int J Dev Neurosci 1994;12:337-342.
45. Tabor CW and Tabor H. Polyamines. Annu Rev Biochem 1984; 53:749-790.
46. Morgan DML. Polyamines. Essays Biochem 1987;46: 82-115.
47. Cai D, Deng K, Mellado W, Lee J, Ratan RR and Filbin MT. Arginase I and polyamines act downstream from cyclic AMP in overcoming inhibition of axonal growth MAG and myelin in vitro. Neuron 2002;35:711-719.
48. Nishioka K. Introduction to polyamines. In: Nishioka K (ed) Polyamines in Cancer: Basic Mechanisms and Clinical Approaches. New York Springer, 1996; pp 1-5.
49. Schipper RG, Penning LC and Verhofstad AA. Involvement of polyamines in apoptosis. Facts and controversies: effectors or protectors? Cancer Biol 2000;10:55-68.
50. Thomas T and Thomas TJ. Polyamines in cell growth and cell death: molecular mechanisms and therapeutic applications. Cell Mol Life Sci 2001;58:244-258.
51. Auvinen M, Jarvinen K, Hotti A, Okkeri J, Laitinen J, Janne OA, Coffino P, Bergman M, Andersson LC, Alitalo K and Holtta E. Transcriptional regulation of the ornithine decarboxylase gene by c-Myc/Max/Mad network and retinoblastoma protein interacting with c-Myc. Int J Biochem Cell Biol 2003;35:496-521.
52. de la Torre JC. Alzheimer disease as a vascular disorder: Nosological evidence. Stroke 2002;33:1152-1162.
53. Rhodin JA and Thomas T. A vascular connection to Alzheimer's disease. Microcirculation 2001, 8:207-220.
54. Breteler MM, Bots ML, Ott A and Hofman A. Risk factors for vascular disease and dementia. Haemostasis 1998;28:167-173.
55. Roher AE, Esh C, Kokjohn TA, Kalbak W, Luhers DC, Seward JD, Sue LI and Beach TG. Circle of Willis atherosclerosis is a risk factor for sporadic Alzheimer's disease. Arterioscler Thromb Vasc Biol 2003;23:2055-2062.
56. Breteler MM. Vascular involvement in cognitive decline and dementia: epidemiologic evidence from the Rotterdam Study and the Rotterdam Scan Study. Ann N Y Acad Sci 2000;903:457-465.
57. Breteler MM. Vascular risk factors for Alzheimer's disease: an epidemiological study. Neurobiol Aging 2000;21:153-160.
58. Ott A, Stolk RP, Hofman A, van Harskamp F, Grobbee DE and Breteler MM. Association of diabetes mellitus and dementia: the Rotterdam Study. Diabetologia 1996;39: 1392-1397.
59. Ott A, Slooter AJ, Hofman A, van Harskamp F and Witteman JC. Smoking and risk of dementia and Alzheimer's disease in a population-based cohort study: the Rotterdam Study. Lancet 1998;351:1840-1843.
60. Van Duijn CM, Havekes LM, van Broeckhoven C, de Knijff P and Hofman A. Apolipoproyein E genotype and association between smoking and early onset Alzheimer's disease. Br Med J 1995;310:627-631.
61. Graves AB, van Duijn CM, Chandra V, Fratiglioni L, Heyman A, Jorm AF, Kokmen E, Kondo K, Mortimer JA, Rocca WA, Shalat S, Soininen H and Hofman A. Alcohol and tobacco consumption as risk factors for Alzheimer's disease: a collaborative re-analysis of case-controlled studies. Int J Epidemiol 1991;20:S48-S57.
62. Roher AE, Esh C, Kokjohn TA, Kalback W, Luehrs DC, Seward JD, Sue LI and Beach TG. Circle of willis atherosclerosis is a risk factor for sporadic Alzheimer's disease. Thromb Vasc Biol 2003;23;2055-2062.
63. Beach TG, Wilson JR, Sue LI, Newell A, Poston M, Cisneros R, Pandya Y, Esh C, Connor DJ, Sabbagh M, Walker DG and Roher AE. Circle of Willis atherosclerosis: association with Alzheimer's disease, neuritic plaques and neurofibrillary tangles. Acta Neuropathol (Berl) 2007;113:13-21.
64. Hirao K, Ohnishi T, Hirata Y, Yamashita F, Mori T, Moriguchi Y, Matsuda H, Nemoto K, Imabayashi E, Yamada M, Iwamoto T, Arima K and Asada T. The prediction of rapid conversion to Alzheimer's disease in mild cognitive impairment using regional cerebral blood flow SPECT. Neuroimage 2005;28: 1014-1021.
65. Johnson KA, Jones K, Holman BL, Becker J, Spiers PA, Satlin A and Albert MS. Preclinical prediction of Alzheimer's disease using SPECT. Neurology 1998;50:1563-1571.
66. Johnson KA and Albert MS. Perfusion abnormalities in prodromal Alzheimer's disease. Neurobiol Aging 2000;21:289-292.
67. Matsuda H, Mizumura S, Nagao T, Ota T, Iizuka T, Nemoto K, Kimura M, Tateno A, Ishiwata A, Kuji I, Arai H and Homma A. An easy Z-score imaging system for discrimination between very early Alzheimer's disease and controls using brain perfusion SPECT in a multicentre study. Nucl Med Commun 2007;28:199-205.
68. Sparks DL, Sabbagh M, Connor D, Soares H, Lopez J, Stankovic G, Johnson-Traver S, Ziolkowski C and Browne P. Statin therapy in Alzheimer's disease. Acta Neurol Scand Suppl 2006;185:78-86.
69. Zamrini E, McGwin G and Roseman JM. Association between statin use and Alzheimer's disease. Neuroepidemiology 2004;23:94-98.
70. Miida T, Takahashi A, Tanabe N and Ikeuchi T. Can statin therapy really reduce the risk of Alzheimer's disease and slow its progression? Curr Opin Lipidol 2005;16:619-623.
71. Zigman WB, Schupf N, Jenkins EC, Urv TK, Tycko B and Silverman W. Cholesterol level, statin use and Alzheimer's disease in adults with Down syndrome. Neurosci Lett 2007;18; 416:279-284.
72. Petanceska SS, DeRosa S, Olm V, Diaz N, Sharma A, Thomas-Bryant T, Duff K, Pappolla M and Refolo LM.. Statin therapy for Alzheimer's disease: will it work? J Mol Neurosci 2002;19:155-161.
73. Maxwell AJ and Cooke JP. Cardiovascular effects of L-arginine. Curr Opin Nephrol Hypertens 1998;7:63-70.
74. Ignarro LJ, Cirino G, Casini A and Napoli C. Nitric oxide as a signaling molecule in the vascular system: an overview. J Cardiovasc Pharmacol 1999;34:879-886.
75. Walter R, Mark M and Reinhart WH. Pharmacological concentrations of arginine influence human whole blood viscosity independent of nitric oxide synthase activity in vitro. Biochem Biophys Res Commun 2000; 269:687-691.
76. Böger RH, Bode-Böger SM, Szuba A, Tsao PS, Chan JR, Tangphao O, Blaschke TF and Cooke JP. Asymmetric dimethylarginine (ADMA): a novel risk factor for endothelial dysfunction: its role in hypercholesterolemia. Circulation 1998;98:1842-1847.
77. Creager MA, Gallagher SJ, Girerd XJ, Coleman SM, Dzau VJ and Cooke JP. L-Arginine improves endothelium dependent vasodilation in hypercholesterolemic humans. J Clin Invest 1992;90:1248-1253.
78. Cooke JP and Creager A. Endothelial dysfunction in hypercholesterolemia is corrected by L-arginine. Basic Res Cardiol 1991;86(Suppl 2):173-181.
79. Thorne S, Mullen MJ, Clarkson P and Donald AE. Early endothelial dysfunction in adults at risk from atherosclerosis: different responses to L-arginine. J Am Coll Cardiol 1998;32:110-116.
80. Stroes ESG, Koomans HA, DeBruin TWA and Rabelink TJ. Vascular function in the forearm of hypercholesterolemic patients off and on lipid-lowering medication. Lancet 1995;346: 467-471.
81. Clarkson P, Adams MR, Powe AJ, Donald AE, McCredie R, Robinson J, McCarthy SN, Keech A, Celermajer DS and Deanfield JE. Oral L-arginine improves endothelium-dependent dilation in hypercholesterolaemic young adults. J Clin Invest 1996;15;97:1989-1994.
82. Maxwell AJ, Anderson B, Zapien MP and Cooke JP. Endothelial dysfunction in hypercholesterolemia is reversed by nutritional duraproduct designed to enhance nitric oxide activity. Cardiovasc Drugs Ther 2000;14:309-316.
83. Tsao PS, McEvoy LM, Drexler H, Butcher EC and Cooke JP. Enhanced endothelial adhesiveness in hypercholesterolemia is attenuated by L-arginine. Circulation 1994;89: 2176-2182.0
84. Drexler H and Hornig B. Endothelial dysfunction in human disease. J Mol Cell Cardiol 1999;31:51-60.
85. Goumas G, Tentolouris C, Tousoulis D, Stefanadis C and Toutouzas P. Therapeutic modification of the L-arginine-eNOS pathway in cardiovascular diseases. Atherosclerosis 2001;154:255-267.
86. Wolf A, Zalpour C, Theilmeier G, Wang BY, Ma A, Anderson B, Tsao PS and Cooke JP. Dietary L-arginine supplementation normalizes platelet aggregation in hypercholesterolemic humans. J Am Coll Cardiol 1997;29:479-285.
87. Bode-Böger SM, Böger RH, Creutzig A, Tsikas D, Gutzki FM, Alexander K and Frölich JC. L-arginine infusion decreases peripheral arterial resistance and inhibits platelet aggregation in healthy subjects. Clin Sci (Lond) 1994;87:303-310.
88. Theilmeier G, Chan JR, Zalpour C, Anderson B, Wang BY, Wolf A, Tsao PS and Cooke JP. Adhesiveness of mononuclear cells in hypercholesterolemic humans is normalized by dietary L-arginine. Arterioscler Thromb Vasc Biol 1997;17:3557-3564.
89. Kawano H, Motoyama T, Hirai N, Kugiyama K, Yasue H and Ogawa H. Endothelial dysfunction in hypercholesterolemia is improved by L-arginine administration: possible role of oxidative stress. Atherosclerosis 2002;161:375-380.
90. Dhawan V, Handu SS, Nain CK and Ganguly NK. Chronic L-arginine supplementation improves endothelial cell vasoactive functions in hypercholesterolemic and atherosclerotic monkeys. Mol Cell Biochem 2005;269:1-11.
91. Jeremy RW, McCarron H and Sullivan D. Effects of dietary L-arginine on atherosclerosis and endothelium-dependent vasodilation in the hypercholesterolemic rabbit. Response according to treatment duration, anatomic site and sex. Circulation 1996;94:498-506.
92. Verreault R, Kaltenbach G and Berthel M. Hypertension and Alzheimer's disease. Presse Med 2005;34:809-812.
93. Skoog I and Gustafson D. Update on hypertension and Alzheimer's disease. Neurol Res 2006;28:605-611.
94. Siani A, Pagano E, Iacone R, Iacoviello L, Scopacasa F and Strazzullo P. Blood pressure and metabolic changes during dietary L-arginine supplementation in humans. Am J Hypertens 2000;13:547-551.
95. Rector TS, Bank AJ, Mullen KA, Tschumperlin LK, Sih R, Pillai K and Kubo SH. Randomized, double-blind, placebo-controlled study of supplemental oral L-arginine in patients with heart failure. Circulation 1996;93:2135-2141.
96. Galanis DJ, Petrovitch H, Launer LJ, Harris TB, Foley DJ and White LR. Smoking history in middle age and subsequent cognitive performance in elderly Japanese-American men. Am J Epidemiol 1997;145:507-515.
97. Aggarwal NT, Bienias JL, Bennett DA, Wilson RS, Morris MC, Schneider JA, Shah RC and Evans DA. The relation of cigarette smoking to incident Alzheimer's disease in a biracial urban community population. Neuroepidemiology 2006; 26:140-146.
98. Ford AB, Mefrouche Z, Friedland RP and Debanne SM. Smoking and cognitive impairment: a population-based study. J Am Geriatr Soc 1996;44:905-909.
99. Launer LJ, Feskens EJ, Kalmijn S and Kromhout D. Smoking, drinking, and thinking. The Zutphen Elderly Study. Am J Epidemiol 1996;143:219-227.
100. Dickerson TJ and Janda KD. Glycation of the amyloid beta-protein by a nicotine metabolite: a fortuitous chemical dynamic between smoking and Alzheimer's disease. Proc Natl Acad Sci USA 2003;100:8182-8187.
101. Sanderson KJ, van Rij AM, Wade CR and Sutherland WHF. Lipid peroxidation of circulating low density lipoproteins with age, smoking and in peripheral vascular disease. Atherosclerosis 1995;118:45-51.
102. Weber C, Erl W, Weber K and Weber PC. Increased adhesiveness of isolated monocytes to endothelium is prevented by vitamin C intake in smokers. Circulation 1996; 93:1488-1492.
103. Adams MR, Jessup W and Celermajer DS. Cigarette smoking is associated with increased human monocyte adhesion to endothelial cells: reversibility with oral L-arginine but not vitamin C. J Am Coll Cardiol 1997;29:491-497.
104. Panza JA, Casino PR, Badar DM and Quyyumi AA. Effect of increased availability of endothelium-derived nitric oxide precursor on endo-thelium-dependent vascular relaxation in normal subjects and in patients with essential hypertension. Circulation 1993;87: 1475-1481.
105. Taddei S, Mattei P, Virdis A, Sudano I, Ghiadoni L and Salvetti A. Effect of potassium on vasodilation to acetylcholine in essential hypertension. Hypertension 1994;23:485-490.
106. Pritchard KA, Groszek L, Smalley DM, Sessa WC and Wu M. Native low density lipoprotein increases endothelial cell nitric oxide synthase generation of superoxide anion. Circ Res 1995;77:510-518.
107. Palmer RMJ, Ferrige AG and Moncada S. Nitric oxide accounts for the biological activity of endothelium-derived relaxing factor. Nature 1987;327:524-526.
108. Radomski MW, Palmer RMJ and Moncada S. An L-arginine/nitric oxide pathway present in human platelets regulates aggregation. Proc Natl Acad Sci USA 1990;87:5193-5197.
109. Kubes P, Suzuki M and Granger DN. Nitric oxide: an endogenous modulator of leukocyte adhesion. Proc Natl Acad Sci USA 1991;88: 4651-4655.
110. Garg UC and Hassid A. Nitric oxide generating vasodilators and 8-bromocyclic guanosine monophosphate inhibit mitogenesis and proliferation of cultured rat vascular smooth muscle cells. J Clin Invest 1989;83:1774-1777.
111. Zeiher AM, Fisslthaler B, Schray-Utz B and Busse R. Nitric oxide modulates the expression of monocyte chemoattractant protein-1 in cultured human endothelial cells. Circ Res 1995;76:980-986.
112. Hobbs AJ, Higgs A and Moncada S. Inhibition of nitric oxide synthase as a potential therapeutic target. Annu Rev Pharmacol Toxicol 1999;39:191-220.
113. Boger RH and Bode-Boger SM. The clinical pharmacology of L-arginine. Annu Rev Pharmacol Toxicol 2001;41:79-99.
114. Higashi Y, Oshima T, Ono N, Hiraga H, Yoshimura M, Watanabe M, Matsuura H, Kambe M and Kajiyama G. Intravenous administration of L-arginine inhibits angiotensin-converting enzyme in humans. J Clin Endocrinol Metab 1995;80:2198-2202.
115. Piatti P, Fragasso G, Monti LD, Setola E, Lucotti P, Fermo I, Paroni R, Galluccio E, Pozza G, Chierchia S and Margonato A. Acute intravenous L-arginine infusion decreases endothelin-1 levels and improves endothelial function in patients with angina pectoris and normal coronary arteriograms: correlation with asymmetric dimethylarginine levels. Circulation 2003;107:429-436.
116. Halliwell B. Protection against tissue damage in vivo by desferrioxamine: what is its mechanism of action? Free Radic Biol Med 1989;7:645-651.
117. Smith MA, Perry G, Richey PL, Sayre LM, Anderson VE, Beal MF and Kowall N. Oxidative damage in Alzheimer's. Nature 1996;382:120-121.
118. Sayre LM, Zelasko DA, Harris PL, Perry G, Salomon RG and Smith MA. 4-Hydroxynonenal-derived advanced lipid peroxidation end products are increased in Alzheimer's disease. J Neurochem 1997;68: 2092-2097.
119. Smith MA. Alzheimer disease. Int Rev Neurobiol 1998;42:1-54.
120. Nunomura A, Perry G, Pappolla MA, Friedland RP, Hirai K, Chiba S and Smith MA. Neuronal oxidative stress precedes amyloid-beta deposition in Down syndrome. J Neuropathol Exp Neurol 2000;59:1011-1017.
121. Nunomura A, Perry G, Aliev G, Hirai K, Takeda A, Balraj EK, Jones PK, Ghanbari H, Wataya T, Shimohama S, Chiba S, Atwood CS, Petersen RB and Smith MA. Oxidative damage is the earliest event in Alzheimer disease. J Neuropathol Exp Neurol 2001;60:759-767.
122. Zhu X, Raina AK, Lee HG, Casadesus G, Smith MA and Perry G. Oxidative stress signaling in Alzheimer's disease. Brain Res 2004;1000: 32-39.
123. Perry G, Taddeo MA, Nunomura A, Zhu X, Zenteno-Savin T, Drew KL, Shimohama S, Avila J, Castellani RJ and Smith MA. Comparative biology and pathology of oxidative stress in Alzheimer and other neurodegenerative diseases: beyond damage and response. Comp Biochem Physiol C Toxicol Pharmacol 2002;133:507-513.
124. Reddy PH. Amyloid precursor protein-mediated free radicals and oxidative damage: implications for the development and progression of Alzheimer's disease. J Neurochem 2006;96:1-13.
125. Malinski T. Nitric oxide and nitrosative stress in Alzheimer's disease. J Alzheimers Dis 2007;11:207-218.
126. Guix FX, Uribesalgo I, Coma M and Munoz FJ. The physiology and pathophysiology of nitric oxide in the brain. Prog Neurobiol 2005;76: 126-152.
127. Pacher P, Beckman JS and Liaudet L. Nitric oxide and peroxynitrite in health and disease. Physiol Rev 2007;87:315-424.
128. Ridnour LA, Thomas DD, Mancardi D, Espey MG, Miranda KM, Paolocci N, Feelisch M, Fukuto J and Wink DA. The chemistry of nitroxidative stress induced by nitric oxide and reactive nitrogen oxide species. Putting perspective on stressful biological situations. Biol Chem 2004;385:1-10.
129. Hirst DG and Robson T. Nitrosative stress in cancer therapy. Front Biosci 2007;12:3406-3418.
130. 2 and NO on apoptosis involving activation of p38 mitogen-activated protein kinase and caspase-3. J Neurosci Res 2003;72:508-519.
131. Castegna A, Thongboonkerd V, Klein JB, Lynn B, Markesbery WR and Butterfield DA. Proteomic identification of nitrated proteins in Alzheimer's disease brain. J Neurochem 2003;85:1394-1401.
132. Sultana R, Poon HF, Cai J, Pierce WM, Merchant M, Klein JB, Markesbery WR and Butterfield DA. Identification of nitrated proteins in Alzheimer's disease brain using a redox proteomics approach. Neurobiol Dis 2006;22:76-87.
133. Wink DA, Hanbauemr I, Krishna MC, DeGrafej W, Gamson J and Mitchell JB. Nitric oxide protects against cellular damage and cytotoxicity from reactive oxygen species. Proc Natl Acad Sci USA 1993;90:9813-9817.
134. Wink DA, Hanbauer I, Laval F, Cook JA, Kroshna MC and Mitchell JB. Nitric oxide protects against the cytotoxic effects of reactive oxygen species. Ann N Y Acad Sci 1994;738:265-278.
135. Dawson VL, Dawson TM, London ED, Bredt DS and Snyder SH. Nitric oxide mediates glutamate neurotoxicity in primary cortical cultures. Proc Natl Acad Sci USA 1991;88: 6368-6371.
136. Glebov AN and Zinchuk VV. Prooxidant-antioxidant state of the organism during oxidative stress and correction of the L-arginine-NO system. Bull Exp Biol Med 2006; 141:368-370.
137. Dawson VL and Dawson TM. Nitric oxide neurotoxicity. J Chem Neuroanat 1996;10: 179-190
138. Iadecola C. Bright and dark sides of nitric oxide in ischemic brain injury. Trends Neurosci 1997;20:132-139.
139. Tang XQ, Yu HM, Zhi JL, Cui Y, Tang EH, Feng JQ and Chen PX. Inducible nitric oxide synthase and cyclooxgenase-2 mediate protection of hydrogen peroxide preconditioning against apoptosis induced by oxidative stress in PC12 cells. Life Sci 2006; 24;79:870-876.
140. Pomara N, Singh R, Deptula D, Chou JC-Y, Schwartz MB and LeWitt P. Glutamate and other CSF amino acids in Alzheimer's disease. Am J Psychiatry 1992;149:251-254.
141. McFarland R, Blokhin A, Sydnor J, Mariani J and Vogel MW. Oxidative stress, nitric oxide, and the mechanisms of cell death in Lurcher Purkinje cells. Dev Neurobiol 2007;67:1032-1046.
142. Aliev G, Smith MA, Seyidov D, Neal ML, Lamb BT, Nunomura A, Gasimov EK, Vinters HV, Perry G, LaManna JC and Friedland RP. The role of oxidative stress in the pathophysiology of cerebrovascular lesions in Alzheimer's disease. Brain Pathol 2002;12:21-35.
143. Maier CM and Chan PH. Role of superoxide dismutases in oxidative damage and neurodegenerative disorders. Neuroscientist 2002;8:323-334.
144. Miliutina NP, Ananian AA and Shugalei VS. Antiradical and antioxidant effect of arginine and its action on lipid peroxidation in hypoxia. Biull Eksp Biol Med 1990;110:433-435.
145. Maksimovich NE and Maslakov DA. The amino acid L-arginine and the potential for its use in clinical practice. Zdravookhranenie 2003;5:35-37.
146. Sedlak J and Lindsay RH. Estimation of total, protein-bound, and nonprotein sulfhydryl groups in tissue with Ellman's reagent. Anal Biochem 1968;25:192-205.
147. Wink DA, Miranda KM and Esprey MG. Mechanisms of the antioxidant effects of nitric oxide, Antioxid Redox Signal 2000;1: 203-213.
148. Maksimovich NE, Zinchuk VV and Maslakov DA. The degree of oxidative stress in the rat brain during ischemia and reperfusion in conditions of correction of the L-arginine-No system. Neurosci Behav Physiol 2006;36: 373-378.
149. Calabrese V, Bates TE and Stella AM. NO synthase and NO-dependent signal pathways in brain aging and neurodegenerative disorders: the role of oxidant/antioxidant balance. Neurochem Res 2000;25:1315-1341.
150. Bredt DS, Hwang PM and Snyder SH. Localization of nitric oxide synthase indicating a neural role for nitric oxide. Nature 1990; 347:768-770.
151. Robak J and Gryglewski RJ. Nitric oxide donors as scavengers of superoxide anions. Pol J Pharmacol 1993;45:51-58.
152. Zinchuk VV. Involvement of nitric oxide in forming the oxygen binding properties of hemoglobin. Usp Fiziol Nauk 2003;34:33-45.
153. Popov D, Costache G, Georgescu A and Enache M. Beneficial effects of L-arginine supplementation in experimental hyperlipemia-hyperglycemia in the hamster. Cell Tissue Res 2002;308:109-120.
154. Kawano H, Motoyama T, Hirai N, Kugiyama K, Yasue H and Ogawa H. Endothelial dysfunction in hypercholesterolemia is improved by L-arginine administration: possible role of oxidative stress. Atheroslcerosis 2002;161:375-380.
155. Steer P, Millgård J, Basu S, Lithell H, Vessby B, Berne C and Lind L. Vitamin C, diclophenac, and L-arginine protect endothelium-dependent vasodilation against elevated circulating fatty acid levels in humans. Atheroslcerosis 2003;168:65-72.
156. Lin CC, Tsai WC, Chen JY, Li YH, Lin LJ and Chen JH. Supplements of L-arginine attenuate the effects of high-fat meal on endothelial function and oxidative stress. Int J Cardiol 2008;127:331-340.
157. Tsai WC, Li YH, Lin CC, Chao TH and Chen JH. Effects of oxidative stress on endothelial function after a high-fat meal. Clin Sci 2004; 106:315-319.
158. Rosenberg PB. Clinical aspects of inflammation in Alzheimer's disease. Int Rev Psychiatry 2005;17:503-514.
159. McGeer PL and McGeer EG. Local neuroinflammation and the progression of Alzheimer's disease. J Neurovirol 2002;8: 529-538.
160. Walsh DM, Klyubin I, Fadeeva JV, Rowan MJ and Selkoe DJ. Amyloid-beta oligomers: their production, toxicity and therapeutic inhibition. Biochem Soc 2002;30:552-557.
161. Walsh DM and Selkoe DJ. Deciphering the molecular basis of memory failure in Alzheimer's disease. Neuron 2004;44:181-193.
162. Tan J, Town T, Paris D, Mori T, Suo Z, Crawford F, Mattson MP, Flavell RA and Mullan M. Microglial activation resulting from CD40-CD40L interaction after beta-amyloid stimulation. Science 1999;286:2352-2355.
163. Akiyama H, Barger S, Barnum S, Bradt B, Bauer J, Cole GM, Cooper NR, Eikelenboom P, Emmerling M, Fiebich BL, Finch CE, Frautschy S, Griffin WS, Hampel H, Hull M, Landreth G, Lue L, Mrak R, Mackenzie IR, McGeer PL, O'Banion MK, Pachter J, Pasinetti G, Plata-Salaman C, Rogers J, Rydel R, Shen Y, Streit W, Strohmeyer R, Tooyoma I, Van Muiswinkel FL, Veerhuis R, Walker D, Webster S, Wegrzyniak B, Wenk G and Wyss-Coray T. Inflammation and Alzheimer's disease. Neurobiol Aging 2000;21:383-421.
164. Ferencik M, Novak M, Rovensky J and Rybar I. Alzheimer's disease, inflammation and nonsteroidal anti-inflammatory drugs. Bratisl Lek Listy 2001;102:123-132.
165. Pasinetti GM. From epidemiology to therapeutic trials with anti-inflammatory drugs in Alzheimer's disease: the role of NSAIDs and cyclooxygenase in beta-amyloidosis and clinical dementia. J Alzheimers Dis 2002;4:435-445.
166. Hoozemans JJ, Veerhuis R, Rozemuller AJ and Eikelenboom P. Non-steroidal antiinflammatory drugs and cyclooxygenase in Alzheimer's disease. Curr Drug Targets 2003; 4:461-468.
167. Barbul A, Wasserkrug HL, Seifter E, Rettura G, Levenson SM and Efron G. Thymic stimulatory actions of arginine. J Surg Res 1980;29:228.
168. Niijima A and Meguid MM. Influence of systemic arginine-lysine on immune organ function: an electrophysiological study. Brain Res Bull 1998;45:437-441.
169. Kirk SJ, Hurson M, Regan MC, Holt DR, Wasserkrug HL and Barbul A. Arginine stimulates wound healing and immune function in elderly human beings. Surgery 1993;114:155-159.
170. Albina JE, Mills CD, Barbul A, Thirkill CE, Henry WL, Mastrofrancesco B and Caldwell MD. Arginine metabolism in wounds. Am J Physiol 1988;254:459-467.
171. Albina JE, Caldwell MD, Henry WL and Mills CD. Regulation of macrophage functions by L-arginine. J Exp Med 1989;169:1021-1029.
172. Scott GS and Bolton C. L-arginine modifies free radical production and the development of experimental allergic encephalomyelitis. Inflamm Res 2000;49:720-726.
173. Dawson VL, Brahmbhatt HP, Mong JA and Dawson TM. Expression of inducible nitric oxide synthase causes delayed neurotoxicity in primary mixed neuronal-glial cortical cultures. Neuropharmacology 1994;33:1425-1430.
174. Chao CC, Hu S, Sheng WS, Bu D, Bukrinsky MI and Peterson PK. Cytokine-stimulated astrocytes damage human neurons via a nitric oxide mechanism. Glia 1996;16:276-284.
175. Vodovotz Y, Lucia MS, Flanders KC, Chesler L, Xie QW, Smith TW, Weidner J, Mumford R, Webber R, Nathan C, Roberts AB, Lippa CF and Sporn MB. Inducible nitric oxide synthase in tangle-bearing neurons of patients with Alzheimer's disease. J Exp Med 1996;184: 1425-1433.
176. Smith MA, Richey Harris PL, Sayre LM, Beckman JS and Perry G. Widespread peroxynitrite-mediated damage in Alzheimer's disease. J Neurosci 1997;17:2653-2657.
177. Lee SC, Zhao ML, Hirano A and Dickson DW. Inducible nitric oxide synthase immunoreactivity in the Alzheimer disease hippocampus: association with Hirano bodies, neurofibrillary tangles, and senile plaques. J Neuropathol Exp Neurol 1999;58:1163-1169.
178. Bauer MK, Lieb K, Schulze-Osthoff K, Berger M, Gebicke Haerter PJ, Bauer J and Fiebich BL. Expression and regulation of cyclooxygenase-2 in rat microglia. Eur J Biochem 1997;243:726-731.
179. del Zoppo G, Ginis I, Hallenbeck JM, Iadecola C, Wang X and Feuerstein GZ. Inflammation and stroke: putative role for cytokines, adhesion molecules and iNOS in brain response to ischemia. Brain Pathol 2000;10: 95-112.
180. Garthwaite J, Charles SL and Chess-Williams R. Endothelium-derived relaxing factor release on activation of NMDA receptors suggests role as intercellular messenger in the brain. Nature 1988;336:385-388.
181. Dawson TM, Dawson VL and Snyder SH. A novel neuronal messenger molecule in brain: the free radical, nitric oxide. Ann Neurol 1992; 32:297-311.
182. Bon CL and Garthwaite J. On the role of nitric oxide in hippocampal long-term potentiation. J Neurosci 2003;23:1941-1948.
183. Sanders KM and Ward SM. Nitric oxide as a mediator of nonadrenergic
184. Garthwaite J and Boulton CL. Nitric oxide signaling in the central nervous system. Annu Rev Physiol 1995;57:683-706.
185. Thomas S and Robitaille R. Differential frequency-dependent regulation of transmitter release by endogenous nitric oxide at the amphibian neuromuscular synapse. J Neurosci 2001;21:1087-1095.
186. Nickels TJ, Reed GW, Drummond JT, Blevins DE, Lutz MC and Wilson DF. Does nitric oxide modulate transmitter release at the mammalian neuromuscular junction? Clin Exp Pharmacol Physiol 2007; 34:318-326.
187. Hevel JM and Marletta MA. Macrophage nitric oxide synthase: relationship between enzyme-bound tetrahydrobiopterin and synthase activity. Biochemistry 1992;31: 7160-7165.
188. Barford PA, Blair JA, Eggar C, Hamon D, Morar C and Whitburn SB. Tetrahydrobioperin metabolism in the temporal lobe of patients dying with senile dementia of Alzheimer type. J Neurol Neurosurg Psychiatry 1984;47:736-738.
189. Heizel B, John M, Klatt P, Böhme E and Mayer B. Ca2+/ calmodulin-dependent formation of hydrogen peroxide by brain nitric oxide synthase. Biochem J 1992;281:627-630.
190. Iowe SL, Bowen CM, Francis PT and Neary D. Ante mortem cerebral amino acid concentrations indicate selective degeneration of glutamate-enriched neurons in Azheimer's disease. Neuroscience 1990; 38:571-577.
191. Kuiper MA, Teerlink T, Visser JJ, Bergmans PLM, Scheltens P and Wolters Ch. L-Glutamate, L-arginine and L-citrulline levels in cerebrospinal fluid of Parkinson's disease, multiple system atrophy, and Alzheimer's disease patients. J Neural Transmission 2000;107:183-189.
192. McEntee WJ and Crook TH. Glutamate: its role in learning, memory, and the aging brain. Psychopharmacology 1993;111:391-401.
193. Kuiper MA, Visser JJ, Bergmans PLM, Scheltens Ph and Wolters ECh. Decreased cerebrospinal fluid nitrate levels in Parkinson's disease, Alzheimer's disease and Multiple System Atrophy patients. J Neurol Sci 1994;121:46-49.
194. McCarty MF. Vascular nitric oxide may lessen Alzheimer's risk. Med Hypotheses 1998;51: 465-476.
195. Venturini G, Colasanti M, Persichini T, Fioravanti E, Ascensi P, Palomba L, Cantoni O and Musci G. Beta-amyloid inhibits NOS activity by subtracting NADPH availability. FASEB J 2002;16:1970-1972.
196. Wirtz-Brugger F, Giovanni A Guanosine 3,5-cyclic monophosphate mediated inhibition of cell death induced by nerve growth factor withdrawal and beta-amyloid: protective effects of propentofylline. Neuroscience 2000;99:737-750.
197. Troy CM, Rabacchi SA, Friedman WJ, Frappier TF, Brown K and Shelanski ML. Caspase-2 mediates neuronal cell death induced by beta-amyloid. J Neurosci 2000;20:1386-1392.
198. Tran MH, Yamada K, Olariu A, Mizuno M, Ren XH and Nabeshima T. Amyloid b-peptide induces nitric oxide production in rat hippocampus: association with cholinergic dysfunction and amelioration by inducible nitric oxide synthase inhibitors1. FASEB J 2001;15:1407-1409.
199. McCann SM. The nitric oxide hypothesis of brain aging. Exp Gerontol 1997;32:431-440.
200. Wang Q, Rowan MJ and Anwyl R. Beta-amyloid-mediated inhibition of NMDA receptor-dependent long-term potentiation induction involves activation of microglia and stimulation of inducible nitric oxide synthase and superoxide. J Neurosci 2004;24:6049-6056.
201. Monsonego A, Imitola J, Zota V, Oida T and Weiner HL. Microglia-mediated nitric oxide cytotoxicity of T cells following amyloid betapeptide presentation to Th1 cells. J Immunol 2003;171:2216-2224.
202. Qin L, Liu Y, Cooper C, Liu B, Wilson B and Hong JS. Microglia enhance beta-amyloid peptide-induced toxicity in cortical and mesencephalic neurons by producing reactive oxygen species. J Neurochem 2002;83:973-983.
203. Law A, O'Donnel J, Gauthier S and Quirion R. Neuronal and inducible nitric oxide synthase expressions and activities in the hippocampal and cortices of young adult, aged cognitively unimpaired, and impaired Long-Evans rats. Neuroscience 2002;112:267-275.
204. Puzzo D, Vitolo O, Trinchese F, Jacob JP, Palmeri A and Arancio O. Amyloid-beta peptide inhibits activation of the nitric oxide/cGMP/ cAMP-responsive element-binding protein pathway during hippocampal synaptic plasticity. J Neurosci 2005;25:6887-6897.
205. Watson GS and Craft S. Modulation of memory by insulin and glucose: neuropsychological observations in Alzheimer's disease. Eur J Pharmacol 2004; 490:97-113.
206. Meneilly GS, Cheung E, Tessier D, Yakura C and Tuokko H. The effect of improved glycemic control on cognitive functions in the elderly patient with diabetes. J Gerontol 1993; 48:117-121.
207. Razay G and Wilcock GK. Hyperinsulinaemia and Alzheimer's disease. Age Ageing 1994; 23:396-399.
208. Small GW, Ercoli LM, Silverman DH, Huang SC, Komo S, Bookheimer SY, Lavretsky H, Miller K, Siddarth P, Rasgon NL, Mazziotta JC, Saxena S, Wu HM, Mega MS, Cummings JL, Saunders AM, Pericak-Vance MA, Roses AD, Barrio JR and Phelps ME. Cerebral metabolic and cognitive decline in persons at genetic risk for Alzheimer's disease. Proc Natl Acad Sci USA 2000;97:6037-6042.
209. Garrido GE, Furuie SS, Buchpiguel CA, Bottino CM, Almeida OP, Cid CG, Camargo CH, Castro CC, Glabus MF and Busatto GF. Relation between medial temporal atrophy and functional brain activity during memory processing in Alzheimer's disease: a combined MRI and SPECT study. J Neurol Neurosurg Psychiatry 2002;73:508-516.
210. Squire LR. Memory and the hippocampus: a synthesis from findings with rats, monkeys, and humans. Psychol Rev 1992;99:195-231.
211. Squire LR and Zola SM. Structure and function of declarative and nondeclarative memory systems. Proc Natl Acad Sci USA 1996;93:13515-13522.
212. Manns JR, Hopkins RO, Reed JM, Kitchener EG and Squire LR. Recognition memory and the human hippocampus. Neuron 2003;37: 171-180.
213. Sakamoto S, Ishii K, Hosaka K, Mori T, Sasaki M and Mori E. Detectability of hypometabolic regions in mild Alzheimer disease: function of time after the injection of 2-[fluorine 18]-fluoro-2-deoxy-D-glucose. Am J Neuroradiol 2005;26:843-847.
214. Anchisi D, Borroni B, Franceschi M, Kerrouche N, Kalbe E, Beuthien-Beumann B, Cappa S, Lenz O, Ludecke S, Marcone A, Mielke R, Ortelli P, Padovani A, Pelati O, Pupi A, Scarpini E, Weisenbach S, Herholz K, Salmon E, Holthoff V, Sorbi S, Fazio F and Perani D. Heterogeneity of brain glucose metabolism in mild cognitive impairment and clinical progression to Alzheimer disease. Arch Neurol 2005;62:1728-1733.
215. Gong CX, Liu F, Grundke-Iqbal I and Iqbal K. Impaired brain glucose metabolism leads to Alzheimer neurofibrillary degeneration through a decrease in tau O-GlcNAcylation. J Alzheimers Dis 2006;9:1-12.
216. Mosconi L, Tsui WH, Rusinek H, De Santi S, Li Y, Wang GJ, Pupi A, Fowler J and de Leon MJ. Quantitation, regional vulnerability, and kinetic modeling of brain glucose metabolism in mild Alzheimer's disease. Eur J Nucl Med Mol Imaging 2007;34:1467-1479.
217. Craft S, Zallen G and Baker D. Glucose and memory in mild senile dementia of the Alzheimer type. J Clin Exp Neuropsychol 1992; 14:253-267.
218. Benton D, Owens DS and Parker PY. Blood glucose influences memory and attention in young adults. Neuropsychologia 1994;32: 595-607.
219. Allen JB, Gross AM, Aloia MS and Billingsley C. The effects of glucose on nonmemory cognitive functioning in the elderly. Neuropsychologia 1996;34:459-465.
220. Lidder JK, Sunram PG and Foster SI. Glucose and memory: fractionation of enhancement effects? Psychopharmacology (Berl) 1998; 137:259-270.
221. Sunram-Lea SI, Foster JK, Durlach P and Perez C. The effect of retrograde and anterograde glucose administration on memory performance in healthy young adults. Behav Brain Res 2002;134:505-516.
222. Craft S, Dagogo-Jack SE, Wiethop BV, Murphy C, Nevins RT and Fleischman S. Effects of hyperglycemia on memory and hormone levels in dementia of the Alzheimer type: a longitudinal study. Neurosci 1993;107:926-940.
223. Manning CA, Honn VJ, Stone WS, Jane JS and Gold PE. Glucose effects on cognition in adults with Down's syndrome. Neuropsychology 1998;12:479-484.
224. Stone CA, Korol WS, Gold DL and Manning PE. Glucose enhancement of 24-h memory retrieval in healthy elderly humans. Behav Brain Res 1998;93:71-76.
225. Ragozzino ME, Unick KE and Gold PE. Hippocampal acetylcholine release during memory testing in rats: augmentation by glucose. Proc Natl Acad Sci USA 1996;93: 4693-4698.
226. Ragozzino ME, Arankowsky-Sandoval G. and Gold PE. Glucose attenuates the effect of combined muscarinic-nicotinic receptor blockade on spontaneous alternation. Eur J Pharmacol 1994;256:31-36.
227. Stone WS, Rudd RJ and Gold PE. Glucose attenuation of atropine-induced deficits in paradoxical sleep and memory. Brain Res 1995;694:133-138.
228. Kopf SR and Baratti CM. Effects of posttraining administration of glucose on retention of a habituation response in mice: participation of a central cholinergic mechanism. Neurobiol Learn Mem 1996;65: 253-260.
229. Okaichi Y and Okaichi H. Effects of glucose on scopolamine-induced learning deficits in rats performing the Morris water maze task. Neurobiol Learn Mem 2000;74:65-79.
230. Degroot A, Kornecook T, Quirion R, DeBow S and Parent MB. Glucose increases hippocampal extracellular acetylcholine levels upon activation of septal GABA receptors. Brain Res 2003;979:71-77.
231. Watson GS and Craft S. Modulation of memory by insulin and glucose: neuropsychological observations in Alzheimer's disease. Eur J Pharmacol 2004; 490:97-113.
232. Wilson RS, Barnes LL, Mendes de Leon CF, Aggarwal NT, Schneider JS, Bach J, Pilat J, Beckett LA, Arnold SE, Evans DA and Bennett DA. Depressive symptoms, cognitive decline and risk of AD in older persons. Neurology 2002;59:364-370.
233. Saydah SH, Brancati FL, Golden SH, Fradkin J and Harris MI. Depressive symptoms and the risk of type 2 diabetes mellitus in a US sample. Diabetes Metab Res Rev 2003;19: 202-208.
234. Arvanitakis Z, Wilson RS, Bienias JL, Evans DA and Bennett DA. Diabetes mellitus and risk of Alzheimer disease and decline in cognitive function. Arch Neurol 2004;61:661-666.
235. Gispen WH and Biessels GJ. Cognition and synaptic plasticity in diabetes mellitus. Trends Neurosci 2000;23:542-549.
236. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 2001;414:813-820.
237. Biessels GJ, Van der Heide LP, Kamal A, Bleys RL and Gispen WH. Ageing and diabetes: implications for brain function. Eur J Pharmacol 2002;441:1-14.
238. Meigs JB. Invited commentary: insulin resistance syndrome? Syndrome X? Multiple metabolic syndrome? A syndrome at all? Factor analysis reveals patterns in the fabric of correlated metabolic risk factors. Am J Epidemiol 2000;152:908-911.
239. Hoyer S and Lannert H. Inhibition of the neuronal insulin receptor causes Alzheimer-like disturbances in oxidative/energy brain metabolism and in behavior in adult rats. Ann N Y Acad Sci 1999;893:301-303.
240. Frolich L, Blum-Degen D, Riederer P and Hoyer S. Disturbance in the neuronal insulin receptor signal transduction in sporadic Alzheimer's disease. Ann N Y Acad Sci 1999; 893:290-293.
241. Hoyer S, Lee SK, Loffler T and Schliebs R. Inhibition of the neuronal insulin receptor. An in vivo model for sporadic Alzheimer disease? Ann N Y Acad Sci 2000;920:256-258.
242. Craft S, Peskind E, Schwartz MW, Schellenberg GD, Raskind M and Porte D Jr. Cerebrospinal fluid and plasma insulin levels in Alzheimer's disease: relationship to severity of dementia and apolipoprotein E genotype. Neurology 1998;50:164-168.
243. Messier C. Diabetes, Alzheimer's disease and apolipoprotein genotype. Exp Gerontol 2003; 38:941-946.
244. Craft S, Newcomer J, Kanne S, Dagogo-Jack S, Cryer P, Sheline Y, Luby J, Dagogo-Jack A and Alderson A. Memory improvement following induced hyperinsulinemia in Alzheimer's disease. Neurobiol Aging 1996;17:123-130.
245. Craft S, Asthana S, Newcomer JW, Wilkinson CW, Matos IT, Baker LD, Cherrier M, Lofgreen C, Latendresse S, Petrova A, Plymate S, Raskind M, Grimwood K and Veith RC. Enhancement of memory in Alzheimer disease with insulin and somatostatin, but not glucose. Arch Gen Psychiatry 1999;56: 1135-1140.
246. Craft S, Asthana S, Cook DG, Baker LD, Cherrier M, Purganan K, Wait C, Petrova A, Latendresse S, Watson GS, Newcomer JW, Schellenberg GD and Krohn AJ. Insulin dose-response effects on memory and plasma amyloid precursor protein in Alzheimer's disease: interactions with apolipoprotein E genotype. Psychoneuroendocrinology 2003; 28:809-822.
247. Gasparini L, Netzer WJ, Greengard P and Xu H. Does insulin dysfunction play a role in Alzheimer's disease? Trends Pharmacol Sci 2002;23:288-293.
248. Skeberdis VA, Lan J, Zheng X, Zukin RS and Bennett MV. Insulin promotes rapid delivery of N-methyl-D-aspartate receptors to the cell surface by exocytosis. Proc Natl Acad Sci USA 2001;98:3561-3566.
249. Byrne JH, In: Squire LR, Bloom FE, McConnell SK, Roberts JL, Spitzer NC and Zigmond MJ. (Eds.). Learning and memory: basic mechanisms. Fundamental Neuroscience. Academic Press, San Diego, CA. 2003; pp1276-1298.
250. Davies MG, Ramkumar V, Gettys TW and Hagen PO. The expression and function of G-proteins in experimental intimal hyperplasia. J Clin Invest 1994;94:680-1689.
251. Gilligan DM, Guetta V, Panza JA, Garcia CE, Quyyumi AA and Cannon RO. Selective loss of microvascular endothelial function in human hypercholesterolemia. Circulation 1994;90: 35-41.
252. Mancusi G, Hutter C, Baumgartner-Parzer S, Schmidt K, Schutz W and Sexl V. High-glucose incubation of human umbilical-vein endothelial cells does not alter expression and function either of G-protein alpha-subunits or of endothelial NO synthase. Biochem J 1996;315:281-287.
253. Sobrevia L, Cesare P, Yudilevich DL and Mann GE. Diabetes-induced activation of y+ and nitric oxide synthase in human endothelial cells: association with membrane hyperpolarization. J Physiol 1995;489:183-192.
254. Pieper GM and Peltier BA. Amelioration by l-arginine of a dysfunctional arginine/nitric oxide pathway in diabetic endothelium. J Cardiovasc Pharmacol 1995;25:397-403.
255. Pieper GM, Siebeneich W, Moore-Hilton G and Roza AM. Reversal by L-arginine of a dysfunctional arginine/nitric oxide pathway in the endothelium of the genetic diabetic BB rat. Diabetologia 1997;40:910-915.
256. Knowles RG and Moncada S. Review article: nitric oxide synthases in mammals. Biochem J 1994;298:249-258.
257. 2 in high-glucose medium. Diabetes 1995; 44:520-526.
258. Honing MLH, Morrison PJ, Banga JD, Stroes ESG and Rabelink TJ. Nitric oxide availability in diabetes mellitus. Diabetes Metab Rev 1998;14:241-249.
259. Ragoobirsingh D, McGrowder D, Dasgupta T and Brown P. The effect of nitric oxide on glucose metabolism. Mol Cell Biochem 2004; 263:29-34.
260. Jobgen WS, Fried SK, Fu WJ, Meininger CJ and Wu G. Regulatory role for the arginine-nitric oxide pathway in metabolism of energy substrates. J Nutr Biochem 2006;17:571-588.
261. Kohli R, Meininger CJ, Haynes TE, Yan W, Self JT and Wu G. Dietary L-arginine supplementation enhances endothelial nitric oxide synthesis in streptozotocin-induced diabetic rats. J Nutr 2004;134:600-608.
262. Fu WJ, Haynes TE, Kohli R, Hu J, Shi W, Spencer TE, Carroll RJ, Meininger CJ and Wu G. Dietary L-arginine supplementation reduces fat mass in Zucker diabetic fatty rats. J Nutr 2005;135:714-721.
263. Balon TW. Role of nitric oxide in contraction induced glucose transport. Adv Exp Med Biol 1998;441:87-95.
264. Bergandi L, Silvagno F, Russo I, Riganti C, Anfossi G, Aldieri E, Ghigo D, Trovati M and Bosia A. Insulin stimulates glucose transport via nitric oxide/cyclic GMP pathway in human vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 2003;23:2215-2221.
265. Tanaka T, Nakatani K, Morioka K, Urakawa H, Maruyama N, Kitagawa N, Katsuki A, Araki-Sasaki R, Hori Y, Gabazza EC, Yano Y, Wada H, Nobori T, Sumida Y and Adachi Y. Nitric oxide stimulates glucose transport through insulinin-dependent GLUT4 translocation in 3T3-L1 adipocytes. Eur J Endocrinol 2003;149:61-67.
266. Higaki Y, Hirshman MF, Fujii N and Laurie J. Nitric oxide increases glucose uptake through a mechanism that is distinct from the insulin and contraction pathways in rat skeletal muscle. Diabetes 2001;50:241-247.
267. Henstridge DC, Kingwell BA, Formosa MF, Drew BG, McConell GK and Duffy SJ. Effects of the nitric oxide donor, sodium nitroprusside, on resting leg glucose uptake in patients with type 2 diabetes. Diabetologia 2005;48:2602-2608.
268. McGrowder D, Ragoobirsingh D and Brown P. Acute effects of exogenous nitric oxide on glucose uptake in skeletal muscle of normoglycaemic and diabetic rats. Med Sci Monit 2006;12:28-35.
269. McGrowder D, Ragoobirsingh D and Brown P. Modulation of glucose uptake in adipose tissue by nitric oxide-generating compounds. J Biosci 2006;31:347-354.
270. Schmidt HH, Warner TD, Ishii K, Sheng H and Murad F. Insulin secretion from pancreatic B cells caused by L-arginine-derived nitrogen oxide. Science 1992;255:721-723.
271. Smukler SR, Tang L, Wheeler MB and Salapatek AMF. Exogenous nitric oxide and endogenous glucose-stimulated {beta}-cell nitric oxide augment insulin release. Diabetes 2002;51:3450-3460.
272. Thams P and Capito K. L-Arginine stimulation of glucose-induced insulin secretion through membrane depolarization and independent of nitric oxide. Eur J Endocrinol 1999;140:87-93.
273. Muniappan L and Ozcan S. Induction of insulin secretion in engineered liver cells by nitric oxide. BMC Physiol 2007;17;7:11.
274. Guarino MP, Correia NC, Lautt WW and Macedo MP. Insulin sensitivity is mediated by the activation of the ACh/NO/cGMP pathway in rat liver. Am J Physiol Gastrointest Liver Physiol 2004;287:527-532.
275. Guarino MP and Macedo MP. Co-administration of glutathione and nitric oxide enhances insulin sensitivity in Wistar rats. Br J Pharmacol 2006;147:959-965.
276. Juan CC, Chang CL, Chuang TY, Huang SW, Kwok CF and Ho LT. Insulin sensitivity and resistin expression in nitric oxide-deficient rats. Diabetologia 2006;49:3017-3026.
277. Butler R, Morris AD and Struthers AD. Systemic nitric oxide synthase inhibition increases insulin sensitivity in man. Clin Sci (Lond) 1998;94:175-180.
278. Pollard HB, Adeyemo M, Dhariwal K, Levine M, Caohuy H, Markey S, Markey CJ and Youdim MB. The goldfish as a drug discovery vehicle for Parkinson's disease and other neurodegenerative disorders. Ann N Y Acad Sci 1993;28;679:317-320.
279. Barker RA. Prospects for the treatment of Parkinson's disease using neural grafts. Expert Opin Pharmacother 2000;1:889-902.
280. Reynolds GP. Antipsychotic drug use in neurodegenerative disease in the elderly: problems and potential from a pharmacological perspective. Expert Opin Pharmacother 2001;2:543-548.
281. Poulter MO, Payne KB and Steiner JP. Neuroimmunophilins: a novel drug therapy for the reversal of neurodegenerative disease? Neuroscience 2004;128:1-6.
282. Kuan WL and Barker RA. New therapeutic approaches to Parkinson's disease including neural transplants. Nerorehabil Neural Repair 2005;19:155-181.
283. Waldmeier P, Bozyczko-Coyne D, Williams M and Vaught JL. Recent clinical failures in Parkinson's disease with apoptosis inhibitors underline the need for a paradigm shift in drug discovery for neurodegenerative diseases. Biochem Pharmacol 2006;72: 1197-1206.
284. Melnikova I. Therapies for Alzheimer's disease. Nat Rev Drug Discov 2007;6:341-342.
285. Gage FH. Structural plasticity: cause, result, or correlate of depression. Biol Psychiatry 2000;48:713-714.
286. Alvarez-Buylla A and Garcia-Verdugo JM. Neurogenesis in adult subventricular zone. J Neurosci 2002;22:629-634.
287. Alvarez-Buylla A, Seri B and Doetsch F. Identification of neural stem cells in the adult vertebrate brain. Brain Res Bull 2002;57: 751-758.
288. Gage FH. Neurogenesis in the adult brain. J Neurosci 2002;22:612-613.
289. Eriksson PS, Perfilieva E, Bjork-Eriksson T, Alborn AM, Nordborg C, Peterson DA and Gage FH. Neurogenesis in the adult human hippocampus. Nat Med 1998;4:1313-1317.
290. Kornack DR and Rakic P. Continuation of neurogenesis in the hippocampus of the adult macaque monkey. Proc Natl Acad Sci USA 1999;96:5768-5773.
291. van Praag H, Schlinder AF, Christle BR, Toni N, Palmer TD and Gage FH. Functional neurogenesis in the adult hippocampus. Nature 2002;415:1030-1034.
292. Carleton A, Petreanu LT, Lansford R, Alvarez-Buylla A and Lledo PM. Becoming a new neuron in the adult olfactory bulb. Nat Neurosci 2003;6:507-518.
293. Belluzzi O, Benedusi M, Ackman M and LoTurco JJ. Electrophysiological differentiation of new neurons in the olfactory bulb. J Neurosci 2003;23:10411-10418.
294. Lee SH, Lumelsky N, Studer L, Auerbach JM and McKay RD. Efficient generation of midbrain and hindbrain neurons from mouse embryonic stem cells. Nat Biotechnol 2000; 18:675-679.
295. Tropepe V, Hitoshi S, Sirard C, Mak TW, Rossant J and van der Kooy D. Direct neural fate specification from embryonic stem cells: a primitive mammalian neural stem cell stage acquired through a default mechanism. Neuron 2001;30:65-78.
296. Bjorklund LM, Sanchez-Pernaute T, Chung S, Anderson T, Chen I, Chen Y, McNaught K, Brownell AL, Jenkins BG, Wahlestedt C, Kim KS and Isacson O. Embryonic stem cells develop into functional dopaminergic neurons after transplantation in a Parkinson rat model. Proc Natl Acad Sci USA 2002;99:2344-2349.
297. Rathjen J, Haines BP, Hudson KM, Nesci A, Dunn S and Rathjen PD. Directed differentiation of pluripotent cells to neural lineages: homogeneous formation and differentiation of a neurectoderm population. Development 2002;129:2649-2661.
298. Tabar V, Panagiotakos G, Greenberg ED, Chan BK, Sadelain M, Gutin PH and Studer L. Migration and differentiation of neural precursors derived from human embryonic stem cells in the rat brain. Nat Biotechnol 2005;23:601-606.
299. Ideda H, Osakada F, Watanabe K, Mizuseki K, Haraguchi T, Miyoshi H, Kamiya D, Honda Y, Sasai N, Yoshimura N, Takahashi M and Sasai Y. Generation of Rx+/Pax6+ neural retinal precursors from embryonic stem cells. Proc Natl Acad Sci USA 2005;102:11331-11336.
300. Lumelsky N, Lee S-H, Nguyen LJ, Sanchez-Pernaute R, Bankiewicz K and McKay R. Dopamine neurons derived from embryonic stem cells function in an animal model of Parkinson's disease. Nature 2002;418:50-56.
301. Kim SU, Park IH, Kim TH, Kim KS, Choi HB, Hong SH, Bang JH, Lee MA, Joo IS, Lee CS and Kim YS. Brain transplantation of human neural stem cells transduced with tyrosine hydroxylase and GTP cyclohydrolase 1 provides functional improvement in animal models of Parkinson disease. Neuropathology 2006;26:129-140.
302. Fu YS, Cheng YC, Lin MA, Cheng H, Chu PM, Chou SC, Shih YH, Ko M-H and Sung MS. Conversion of human umbilical cord mesenchymal stem cells in Wharton's jelly to dopaminergic neurons in vitro: potential therapeutic application for Parkinsonism. Stem Cells 2006;24:115-124.
303. Kee NJ, Preston E and Woitowicz JM. Enhanced neurogenesis after transient global ischemia in the dentate gyrus of the rat. Exp Brain Res 2001;136:313-320.
304. van Praag H, Schinder AF, Christie BR, Toni N, Palmer TD and Gage FH. Functional neurogenesis in the adult hippocampus. Nature 2002;415:1030-1034.
305. Song HJ, Stevens CF and Gage FH. Neural stem cells from adult hippocampus develop essential properties of functional CNS neurons. Nat Neurosci 2002;5:438-445.
306. Rodriguez PC, Quiceno DG and Ochoa AC. L-arginine availability regulates T-lymphocyte cell-cycle progression. Blood 2007;109: 1568-1573.
307. Hua TC and Moochhala SM. Influence of L-arginine, aminoguanidine, and NG-nitro-L-arginine methyl ester (L-name) on the survival rate in a rat model of hemorrhagic shock. Shock 1999;11:51-57.
308. Dodd F, Limoges M, Boudreau RT, Rowden G, Murphy PR and Too CK. L-arginine inhibits apoptosis via a NO-dependent mechanism in Nb2 lymphoma cells. J Cell Biochem 2000;77: 624-634.
309. Holm AM, Andersen CB, Hauns S and Hansen PR. Effects of L-arginine on vascular smooth muscle cell proliferation and apoptosis after balloon injury. Scand Cardiovasc J 2000;34: 28-32.
310. Erden CD, Ekmekci A, Sahin FI, Ergün MA, Oztürk G and Erbas D. L-arginine and mitomycin C-induced nitric oxide release and apoptosis in human lymphocytes. Cell Biol Int 2003;27:337-340.
311. Suschek CV, Schnorr O, Hemmrich K, Aust O, Klotz LO, Sies H and Kolb-Bachofen V. Critical role of L-arginine in endothelial cell survival during oxidative stress. Circulation 2003; 107:2607-2614.
312. Hammerschmidt S, Kuhn H, Grasenack T, Gessner C and Wirtz H. Apoptosis and necrosis induced by cyclic mechanical stretching in alveolar type-II-cells-influence of captopril and L-arginine. Pneumologie 2004; 58:222-229.
313. Ingram A, Parbtani A, Thai K, Ly H, Shankland SJ, Morrissey G and Scholey JW. Dietary supplementation with L-arginine limits cell proliferation in the remnant glomerulus. Kidney Int 1995;48:1857-1865.
314. Shima Y, Maeda T, Aizawa S, Tsuboi I, Kobayashi D, Kato R and Tamai I. L-arginine import via cationic amino acid transporter CAT1 is essential for both differentiation and proliferation of erythrocytes. Blood 2006;107: 1352-1356.
315. Becker-Catania SG, Gregory TL, Yang Y, Gau C-L, de Vellis J, Cederbaum SD and Iyer RK. Loss of arginase I results in increased proliferation of neural stem cells. J Neurosci Res 2006;84:735-746.
316. De Jonge WJ, Marescau B, D'Hooge R, De Deyn PP, Hallemeesch MM, Deutz NE, Ruijter JM and Lamers WH. Overexpression of arginase alters circulating and tissue amino acids and guanidine compounds and affects neuromotor behavior in mice. J Nutr 2001; 131:2732-2740.
317. Cai D, Deng K, Mellado W, Lee J, Ratan RR and Filbin MT. Arginase I and polyamines act downstream from cyclic AMP in overcoming inhibition of axonal growth MAG and myelin in vitro. Neuron 2002;35:711-719.
318. Esch F, Lin KI, Hills A, Zaman K, Baraban JM, Chatterjee S, Rubin L, Ash DE and Ratan RR. Purification of a multipotent antideath activity from bovine liver and its identification as arginase: nitric oxide-independent inhibition of neuronal apoptosis. J Neurosci 1998;18: 4083-4095.
319. Estévez AG, Sahawneh MA, Lange PS, Bae N, Egea M and Ratan RR. Arginase 1 regulation of nitric oxide production is key to survival of trophic factor-deprived motor neurons. J Neurosci 2006;26:8512-8516.
320. Du C, Hu R, Csernansky CA, Hsu CY and Choi DW. Additive neuroprotective effects of dextrorphan and cycloheximide in rats subjected to transient focal cerebral ischemia. Brain Res 1996;718:233-236.
321. Du C, Hu R, Csernansky CA, Hsu CY and Choi DW. Very delayed infarction after focal cerebral ischemia: a role for apoptosis? J Cereb Blood Flow Metab 1996;16:195-201.
322. Cai D, Qiu J, Cao Z, McAtee M, Bregman BS and Filbin MT. Neuronal cyclic AMP controls the developmental loss in ability of axons to regenerate. J Neurosci 2001;21:4731-4739.
323. Dawson VL, Dawson TM, London ED, Bredt DS and Snyder SH. Nitric oxide mediates glutamate neurotoxicity in primary cortical cultures. Proc Natl Acad Sci USA 1991;88: 6368-6371.
324. Sonoki T, Nagasaki A, Gotoh T, Takiguchi M, Takeya M, Matsuzaki H and Mori M. Coinduction of nitric-oxide synthase and arginase I in cultured rat peritoneal macrophages and rat tissues in vivo by lipopolysaccharide. J Biol Chem 1997;272: 3689-3693.
325. Wallace HM, Fraser AV and Hughes A. A perspective of polyamine metabolism. Biochem J 2003;376:1-14.
326. Seiler N. Polyamine metabolism and function in brain. Neurochem Int 1981;3:95-110.
327. Slotkin TA and Bartolome J. Role of ornithine decarboxylase and the polyamines in nervous system development: A review. Brain Res Bull 1986;17:307-320.
328. Schweitzer L, Robbins AJ and Slotkin TA. Dendritic development of Purkinje and granule cells in the cerebellar cortex of rats treated postnatally with alpha-difluoromethylornithine. J Neuropathol Exp Neurol 1989;48:11-22.
329. Harada J and Sugimoto M. Polyamines prevent apoptotic cell death in cultured cerebellar granule neurons. Brain Res 1997; 753:251-259.
330. Chu PJ, Saito H and Abe K. Polyamines promote regeneration of injured axons of cultured rat hippocampal neurons. Brain Res 1995;673:233-241.
331. Malaterre J, Strambi C, Aouane A, Strambi A, Rougon G and Cayre M. A novel role for polyamines in adult neurogenesis in rodent brain. Eur J Neurosci 2004;20:317-330.
332. Cayre M, Malaterre M, Strambi C, Charpin P, Ternaux J-P and Strambi A. Short- and long-chain natural polyamines play specific roles in adult cricket neuroblast proliferation and neuron Differentiation in Vitro. J Neurobiol 2001;48:315-324.
333. Thomas T and Thomas TJ. Regulation of cyclin B1 by estradiol and polyamines in MCF-7 breast cancer cells. Cancer Res 1994;54: 1077-1084.
334. Thomas T, Gallo MA, Klinge CM and Thomas TJ. Polyamine-mediated conformational perturbations in DNA alter the binding of estrogen receptor to poly(dG-m5dC) z poly(dG-m5dC) and a plasmid containing the estrogen response element. J Steroid Biochem Mol Biol 1995;54:89-99.
335. Kaminska B, Kaczmarek L and Grzelakowska-Sztabert B. Inhibitors of polyamine biosynthesis affect the expression of genes encoding cytoskeletal proteins. FEBS Lett 1992;304:198-200.
336. Filhol O, Loue-Mackenbach P, Cochet C and Chambaz EM. Casein kinase II and polyamines may interact in the response of adrenocortical cells to their trophic hormone. Biochem Biophys Res Comm 1991;180:623-630.
337. Ulloa L, Diaz-Nido J and Avila J. Depletion of casein kinase II by antisense oligonucleotide prevents neuritogenesis in neuroblastoma cells. EMBO J 1993;12:1633-1640.
338. Packham G and Cleveland JL. Ornithine decarboxylase is a mediator of c-Myc-induced apoptosis. Mol Cell Biol 1994;14:5741-5747.
339. Packham G and Cleveland JL. The role of ornithine decarboxylase in c-Myc-induced apoptosis. Curr Top Microbiol Immunol 1995; 194:283-290.
340. Sparapani M, Dall'Olio R, Gandolfi O, Ciani E and Contestabile A. Neurotoxicity of polyamines and pharmacological neuroprotection in cultures of rat cerebellar granule cells. Exp Neurol 1997;148:157-166.
341. Brunton VG, Grant MH and Wallace HM. Mechanisms of spermine toxicity in baby-hamster kidney BHK cells. Biochem J 1991; 280:193-198.
342. Gilad GM and Gilad VH. Polyamines affect growth of cultured rat cerebellar neurons in different sera. Int J Deĺ Neurosci 1986;4:195-208.
343. Seiler N. Pharmacological properties of the natural polyamines and their depletion by biosynthesis inhibitors as a therapeutic approach. Prog Drug Res 1991;37:107-159.
344. Johnson TD. Modulation of channel function by polyamines. Trends Pharmacol Sci 1996; 17:22-27.
345. Gilad GM, Dornay M and Gilad VH. Polyamine treatment in early development leads to increased numbers of rat sympathetic neurons. Brain Res 1985;348:363-366.
346. Abe K, Chida N, Nishiyama N and Saito H. Spermine promotes the survival of primary cultured brain neurons. Brain Res 1993;605: 322-326.
347. Chu PJ, Saito H and Abe K. Polyamines promote neurite elongation of cultured rat hippocampal neurons. Neurosci Res 1994;19: 155-160.
348. Redman C, Xu MJ, Peng YM, Scott JA, Payne C, Clark LC and Nelson MA. Involvement of polyamines in selenomethionine induced apoptosis and mitotic alterations in human tumor cells. Carcinogenesis 1997;18:1195-1202.
349. Morrison B 3rd, Pringle AK, McManus T, Ellard J, Bradley M, Signorelli F, Iannotti F and Sundstrom LE. L-arginyl-3,4-spermidine is neuroprotective in several in vitro models of neurodegeneration and in vivo ischaemia without suppressing synaptic transmission. Br J Pharmacol 2002;137:1255-1268.
350. Gilad GM and Gilad VH. Polyamines can protect against ischemia-induced nerve cell death in gerbil forebrain. Exp Neurol 1991; 111:349-355.
351. Kindy MS, Hu Y, Dempsy RJ and Cereb J. Blockade of ornithine decarboxylase enzyme protects against ischemic brain damage. Blood Flow Metab 1994;14:1040-1045.
352. Rao AM, Baskaya MK, Maley ME, Prasad MR and Dempsey RJ. Ornithine decarboxylase activity and edema formation in cerebral ischemia of conscious gerbils. J Neurochem 1995;65:2639-2643.
353. Sauer DS, Martin P, Allegrini PR, Bernasconi R, Amacker H and Fagg GE. Differing effects of α-difluoromethylornitine and CGP 40116 on polyamine levels and infarct volume in a rat model of focal cerebral ischemia. Neurosci Lett 1992;41:131-135.
354. Gilad GM and Gilad VH. Polyamines in neurotrauma. Biochem Pharmacol 1992;44: 401-407.
355. Ciani E, Calvanese V, Crochemore C, Bartesaghi R and Contestabile A. Proliferation of cerebellar precursor cells is negatively regulated by nitric oxide in newborn rat. J Cell Sci 2006;119(Pt 15):3161-3170.
356. Torroglosa A, Murillo-Carretero M, Romero-Grimaldi C, Matarredona ER, Campos-Caro A and Estrada C. Nitric oxide decreases subventricular zone stem cell proliferation by inhibition of epidermal growth factor receptor and phosphoinositide-3-kinase/Akt pathway. Stem Cells 2007;25:88-97.
357. Moreno-Lopez B, Romero-Grimaldi C, Noval JA, Murillo-Carretero M, Matarredona ER and Estrada C. Nitric oxide is a physiological inhibitor of neurogenesis in the adult mouse subventricular zone and olfactory bulb. J Neurosci 2004;24:85-95.
358. Cheng A, Wang S, Rao MS and Mattson MP. Nitric oxide acts in a positive feedback loop with BDNF to regulate neural progenitor cell proliferation
359. Matarredona ER, Murillo-Carretero M, Moreno-Lopez B and Estrada C. Nitric oxide synthesis inhibition increases proliferation of neural precursors isolated from the postnatal mouse subventricular zone. Brain Res 2004; 995:274-284.
360. Zhang R, Zhang L, Zhang Z, Wang Y, Lu M, Lapointe M and Chopp M. A nitric oxide donor induces neurogenesis and reduces functional deficits after stroke in rats. Ann Neurol 2001; 50:602-611.
361. Cheng A, Chan SL, Milhavet O, Wang S and Mattson MP. p38 MAP kinase mediates nitric oxide-induced apoptosis of neural progenitor cells. J Biol Chem 2001;276:43320-43327.
362. Palluy O and Rigaud M. Nitric oxide induces cultured cortical neuron apoptosis. Neurosci Lett 1996;208:1-4.
363. Estévez AG, Spear N, Manuel SM, Radi R, Henderson CE, Barbeito L and Beckman JS. Nitric oxide and superoxide contribute to motor neuron apoptosis induced by trophic factor deprivation. J Neurosci 1998;18:923-931.
364. Martin LJ, Chen K and Liu Z. Adult motor neuron apoptosis is mediated by nitric oxide and Fas death receptor linked by DNA damage and p53 activation. J Neurosci 2005; 25:6449-6459.
365. Zhu XJ, Hua Y, Jiang J, Zhou QG, Luo CX, Han X, Lu YM and Zhu DY. Neuronal nitric oxide synthase-derived nitric oxide inhibits neurogenesis in the adult dentate gyrus by down-regulating cyclic AMP response element binding protein phosphorylation. Neuroscience 2006;141:827-836.
366. Fritzen S, Schmitt A, Köth K, Sommer C, Lesch KP and Reif A. Neuronal nitric oxide synthase (NOS-I) knockout increases the survival rate of neural cells in the hippocampus independently of BDNF. Mol Cell Neurosci 2007;35:261-271.
367. Ciani E, Severi S, Contestabile A and Bartesaghi R. Nitric oxide negatively regulates proliferation and promotes neuronal differentiation through N-Myc downregulation. J Cell Sci 2004;117:4727-4737.
368. Park C, Kang M, Kwon YK, Chung JH, Ahn H and Huh Y. Inhibition of neuronal nitric oxide synthase enhances cell proliferation in the dentate gyrus of the adrenalectomized rat. Neurosci Lett 2001;309:9-12.
369. Xiong H, Yamada K, Han D, Nabeshima T, Enikolopov G, Carnahan J and Nawa H. Mutual regulation between the intercellular messengers nitric oxide and brain-derived neurotrophic factor in rodent neocortical neurons. Eur J Neurosci 1999;11:1567-1576.
370. Reif A, Schmitt A, Fritzen S, Chourbaji S, Bartsch C, Urani A, Wycislo M, Mössner R, Sommer C, Gass P and Lesch KP. Differential effect of endothelial nitric oxide synthase (NOS-III) on the regulation of adult neurogenesis and behaviour. Eur J Neurosci 2004;20:885-895.
371. Zhao X, Lu X and Feng Q. Deficiency in endothelial nitric oxide synthase impairs myocardial angiogenesis. Am J Physiol Heart Circ Physiol 2002;283:2371-2378.
372. Chen J, Zacharek A, Zhang C, Jiang H, Li Y, Roberts C, Lu M, Kapke A and Chopp M. Endothelial nitric oxide synthase regulates brain-derived neurotrophic factor expression and neurogenesis after stroke in mice. J Neurosci 2005;25:2366-2375.
373. Dulak J and Jozkowicz A. Regulation of vascular endothelial growth factor synthesis by nitric oxide: facts and controversies. Antioxid Redox Signal 2003;5:123-132.
374. Zhu Y, Jin K, Mao XO and Greenberg DA. Vascular endothelial growth factor promotes proliferation of cortical neuron precursors by regulating E2F expression. FASEB J 2003;17: 186-193.
375. Park JS, Hong GR, Baek SW, Shin DG, Kim YJ and Shim BS. Expression and regulation of endothelial nitric oxide synthase by vascular endothelial growth factor in ECV 304 cells. J Korean Med Sci 2002;17:161-167.
376. Jin K, Zhu Y, Sun Y, Mao XO, Xie L and Greenberg DA. Vascular endothelial growth factor (VEGF) stimulates neurogenesis in vitro and in vivo. Proc Natl Acad Sci USA 2002;99: 11946-11950.
377. Zhu DY, Deng Q, Yao HH, Wang DC, Deng Y and Liu GQ. Inducible nitric oxide synthase expression in the ischemic core and penumbra after transient focal cerebral ischemia in mice. Life Sci 2002;17:1985-1997.
378. Zhu DY, Liu SH, Sun HS and Lu YM. Expression of inducible nitric oxide synthase after focal cerebral ischemia stimulates neurogenesis in the adult rodent dentate gyrus. J Neurosci 2003;23:223-229.
379. Bernabeu R and Sharp FR. NMDA and AMPA/kainite glutamate receptors modulate dentate gyrus neurogenesis and CA3 synapsin-I in normal and ischemic hippocampus. J Cereb Blood Flow Metab 2000;20:1669-1680.
380. Arvidsson A, Kokaia Z and Lindvall O. Nmethyl-D-aspartate receptor-mediated increase of neurogenesis in adult rat dentate gyrus following stroke. Eur J Neurosci 2001; 14:10-18.
381. Cardenas A, Moro MA, Hurtado O, Leza JC, Lorenzo P, Castrillo A, Bodelon OG, Bosca L and Lizasoain I. Implication of glutamate in the expression of inducible nitric oxide synthase after oxygen and glucose deprivation in rat forebrain slices. Neurochem 2000;74:2041-2048.
382. Jander S, Schroeter M and Stoll G. Role of NMDA receptor signaling in the regulation of inflammatory gene expression after focal brain ischemia. J Neuroimmunol 2000;109: 181-187.
383. Qu XW, Wang H, De Plaen IG, Rozenfeld RA and Hsueh W. Neuronal nitric oxide synthase (NOS) regulates the expression of inducible NOS in rat small intestine via modulation of nuclear factor kappa B. FASEB J 2001;15: 439-446.
384. Luo CX, Zhu XJ, Zhou QG, Wang B, Wang W, Cai HH, Sun YJ, Hu M, Jiang J, Hua Y, Han X and Zhu DY. Reduced neuronal nitric oxide synthase is involved in ischemia-induced hippocampal neurogenesis by up-regulating inducible nitric oxide synthase expression. J Neurochem 2007;103:1872-1882.
385. Togashi H, Sasaki M, Frohman E, Taira E, Ratan RR, Dawson TM and Dawson VL. Neuronal (type I) nitric oxide synthase regulates nuclear factor kappaB activity and immunologic (type II) nitric oxide synthase expression. Proc Natl Acad Sci USA 1997;94: 2676-2680.